

44

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C1039/7052
-INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 22, 2001	
		APPLICANT: Weiner et al.	
Sheet 1 of 8	GROUP ART UNIT: 1645	EXAMINER: unknown	

SEP 24 2001
PATENT & TRADEMARK OFFICE

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
J	A1	3,854,480		Zaffaroni	12-17-1974
	A2	3,906,092		Hilleman et al.	09-16-1975
	A3	4,452,775		Kent	06-05-1984
	A4	4,469,863		Ts'o et al.	09-04-1984
	A5	4,675,189		Kent et al.	06-23-1987
	A6	5,023,243		Tullis	06-11-1991
	A7	5,075,109		Tice et al.	12-24-1991
	A8	5,133,974		Paradissis et al.	07-28-1992
	A9	5,212,295		Cook	05-18-1993
	A10	5,248,670		Draper et al.	09-28-1993
	A11	5,359,052		Stee et al.	10-25-1994
	A12	5,407,686		Patel et al.	04-18-1995
	A13	5,506,212		Hoke et al.	04-09-1996
	A14	5,512,668		Stec et al.	04-30-1996
	A15	5,521,302		Cook	05-28-1996
	A16	5,565,354		Ostberg	10-15-1996
	A17	5,567,610		Borrebaeck et al.	10-22-1996
	A18	5,569,825		Lonberg	10-29-1996
	A19	5,571,893		Baker et al.	11-05-1996
	A20	5,585,479		Hoke et al.	12-17-1996
	A21	5,599,797		Cook et al.	02-04-1997
	A22	5,663,153		Hutcherson et al.	09-02-1997
	A23	5,679,647		Carson et al.	10-21-1997
	A24	5,723,335		Hutcherson et al.	03-03-1998
	A25	5,736,152		Dunn	04-07-1998
	A26	5,780,448		Davis	07-14-1998
	A27	5,786,189		Locht et al.	07-28-1998
	A28	5,837,856		Arnold, Jr. et al.	11-17-1998
	A29	5,849,719		Carson et al.	12-15-1998
	A30	5,856,465		Stec et al.	01-05-1999
	A31	5,883,237		Stec et al.	03-16-1999
	A32	6,015,886		Dale et al.	01-18-2000
	A33	6,194,388	B1	Krieg et al.	02-27-2001
	A34	6,207,646	B1	Krieg et al.	03-27-2001
	A35	6,214,804	B1	Felgner et al.	04-10-2001
	A36	6,214,806	B1	Krieg et al.	04-10-2001
	A37	6,218,371	B1	Krieg et al.	04-17-2001
	A38	6,239,116	B1	Krieg et al.	05-29-2001

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
J	B1	EPO	0 092 574	B1		11-02-1983	

562332.2

[Signature] 12/27/02

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C1039/7052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 22, 2001	
		APPLICANT: Weiner et al.	
Sheet 2 of	GROUP ART UNIT: 1645	EXAMINER: unknown	

B2	EPO	0 234 490	B1	09-30-1987
B3	EPO	0 301 758	B1	02-01-1989
B4	EPO	0 468 520	A2	01-29-1992
B5	WIPO	WO91/12811	A1	09-05-1991
B6	WIPO	WO92/03456	A1	03-05-1992
B7	WIPO	WO92/04381	A1	03-19-1992
B8	WIPO	WO92/18522	A1	10-29-1992
B9	WIPO	WO92/21353	A1	12-10-1992
B10	WIPO	WO94/19945	A1	09-15-1994
B11	WIPO	WO95/05853	A1	03-02-1995
B12	WIPO	WO95/26204	A1	10-05-1995
B13	WIPO	WO96/02555	A1	02-01-1996
B14	WIPO	WO96/02560	A1	02-01-1996
B15	WIPO	WO96/35782	A1	11-14-1996
B16	WIPO	WO97/28259	A1	08-07-1997
B17	WIPO	WO98/14210	A1	04-09-1998
B18	WIPO	WO98/16247	A1	04-23-1998
B19	WIPO	WO98/18810	A1	05-07-1998
B20	WIPO	WO98/32462	A1	07-30-1998
B21	WIPO	WO98/37919	A1	09-03-1998
B22	WIPO	WO98/40100	A1	09-17-1998
B23	WIPO	WO98/52581	A1	11-26-1998
B24	WIPO	WO98/55495	A2	12-10-1998
B25	WIPO	WO99/51259	A2	10-14-1999
B26	WIPO	WO99/56755	A1	11-11-1999
B27	WIPO	WO99/58118	A2	11-18-1999
B28	WIPO	WO99/61056	A2	12-02-1999
B29	WIPO	WO00/06588	A1	02-10-2000
B30	WIPO	WO00/14217	A3	03-16-2000
B31	WIPO	WO00/67023	A1	11-09-2000

OTHER ART — NON PATENT LITERATURE DOCUMENTS


Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
Q	C1	AZAD RF et al., Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. <i>Antimicrob Agents Chemother.</i> 1993 Sep;37(9):1945-54.	
	C2	AZUMA I, Biochemical and immunological studies on cellular components of tubercle bacilli. <i>Kekkaku</i> 1992;67(9):45-55.	
	C3	BALLAS ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol.</i> 1996 Sep 1;157(5):1840-5.	
	C4	BAYEVER E et al., Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. <i>Antisense Res Dev.</i> 1993 Winter;3(4):383-90.	
	C5	BEAUCAGE SL et al., Deoxynucleoside phosphoramidites — a new class of key intermediates for deoxypolynucleotide synthesis. <i>Tetrahedron Lett</i> 22:1859, 1981.	
	C6	BENNETT RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. <i>J Clin Invest.</i> 1985 Dec;76(6):2182-90.	

[Handwritten signature] 12/27/02


FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C1039/7052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 22, 2001	
		APPLICANT: Weiner et al.	
		GROUP ART UNIT: 1645	EXAMINER: unknown
Sheet	3	of	

C7	BLAXTER ML et al., Genes expressed in <i>Brugia malayi</i> infective third stage larvae. <i>Mol Biochem Parasitol.</i> 1996 Apr;77(1):77-93.		
C8	BOGGS RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):461-71.		
C9	BRANDA RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. <i>J Lab Clin Med.</i> 1996 Sep;128(3):329-38.		
C10	BRANDA RF et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. <i>Biochem Pharmacol.</i> 1993 May 25;45(10):2037-43.		
C11	CHACE JH et al., Regulation of differentiation in CD5+ and conventional B cells. Sensitivity to LPS-induced differentiation and interferon-gamma-mediated inhibition of differentiation. <i>Clin Immunol Immunopathol.</i> 1993 Sep;68(3):327-32.		
C12	CHANG YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements. <i>J Virol.</i> 1990 Jan;64(1):264-77.		
C13	CHU RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. <i>J Exp Med.</i> 1997 Nov 17;186(10):1623-31.		
C14	COIFFIER B et al., Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. <i>Blood.</i> 1998 Sep 15;92(6):1927-32.		
C15	COWDERY JS et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. <i>J Immunol.</i> 1996 Jun 15;156(12):4570-5.		
C16	CRYSTAL RG, Transfer of genes to humans: early lessons and obstacles to success. <i>Science.</i> 1995 Oct 20;270(5235):404-10.		
C17	DAVIS HL et al., CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. <i>J Immunol.</i> 1998 Jan 15;160(2):870-6.		
C18	DECKER T et al., Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. <i>Blood.</i> 2000 Feb 1;95(3):999-1006.		
C19	ENGLISH U et al., Chemically modified oligonucleotides as probes and inhibitors. <i>Angew Chemie Int Ed Engl.</i> 1991 Jun;30(6):613-29.		
C20	ERB KJ et al., Infection of mice with <i>Mycobacterium bovis</i> - <i>Bacillus Calmette-Guerin</i> (BCG) suppresses allergen-induced airway eosinophilia. <i>J Exp Med.</i> 1998 Feb 16;187(4):561-9.		
C21	ETLINGER HM, Carrier sequence selection--one key to successful vaccines. <i>Immunol Today.</i> 1992 Feb;13(2):52-5.		
C22	FROEHLER BC et al., Synthesis of DNA via deoxynucleoside H-phosphonate intermediates. <i>Nucleic Acids Res.</i> 1986 Jul 11;14(13):5399-407.		
C23	GAFFNEY BL et al., Large-scale oligonucleotide synthesis by the H-phosphonate method. <i>Tetrahedron Lett</i> 29:2619-22 (1988).		
C24	GAREGG PJ et al., Nucleoside H-phosphonates. III. Chemical synthesis of oligodeoxyribonucleotides by the hydrogenphosphonate approach. <i>Tetrahedron Lett</i> 27:4051-4 (1986).		
C25	GAREGG PJ et al., Nucleoside H-phosphonates. IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach. <i>Tetrahedron Lett</i> 27:4055-8 (1986).		
C26	GOODCHILD J, Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. <i>Bioconjugate Chem</i> 1:165-87 (1990).		
C27	GURA T, Antisense has growing pains. <i>Science.</i> 1995 Oct 27;270(5236):575-7.		
C28	HADDEN JW et al., Immunopharmacology. Immunomodulation and immunotherapy. <i>JAMA.</i> 1992 Nov 25;268(20):2964-9.		

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C1039/7052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 22, 2001	
		APPLICANT: Weiner et al.	
		GROUP ART UNIT: 1645	EXAMINER: unknown
Sheet	4	of	






C29	HADDEN JW, Immunostimulants. <i>Trends Pharmacol Sci</i> . 1993 May;14(5):169-74.		
C30	HALPERN MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. <i>Cell Immunol</i> . 1996 Jan 10;167(1):72-8.		
C31	HARTMANN G et al., Mechanism and function of a newly identified CpG DNA motif in human primary B cells. <i>J Immunol</i> . 2000 Jan 15;164(2):944-53.		
C32	HARTMANN G et al., Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. <i>J Pharmacol Exp Ther</i> . 1998 May;285(2):920-8.		
C33	HATZFELD J et al., Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides. <i>J Exp Med</i> . 1991 Oct 1;174(4):925-9.		
C34	HAZENBOS WLW et al., Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). <i>J Immunol</i> . 1998 Sep 15;161(6):3026-32.		
C35	HIGHFIELD PE, Sepsis: the more, the murkier. <i>Biotechnology (NY)</i> . 1994 Aug;12(8):828.		
C36	HOEFFLER JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions. <i>Mol Endocrinol</i> . 1991 Feb;5(2):256-66.		
C37	IGUCHI-ARIGA SM et al., CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. <i>Genes Dev</i> . 1989 May;3(5):612-9.		
C38	ISHIKAWA R et al., IFN induction and associated changes in splenic leukocyte distribution. <i>J Immunol</i> . 1993 May 1;150(9):3713-27.		
C39	IVERSEN PL et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. <i>Antisense Res Dev</i> . 1994 Spring;4(1):43-52.		
C40	JAKOBOVITS A et al., Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production. <i>Proc Natl Acad Sci USA</i> . 1993 Mar 15;90(6):2551-5.		
C41	JAKWAY JP et al., Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products. <i>J Immunol</i> . 1986 Oct 1;137(7):2225-31.		
C42	JAROSZEWSKI JW et al., Cellular uptake of antisense oligodeoxynucleotides. <i>Adv Drug Del Rev</i> . 1991;6(3):235-50.		
C43	KATAOKA T et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG. <i>Jpn J Cancer Res</i> . 1992 Mar;83(3):244-7.		
C44	KATAOKA T et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. <i>Jpn J Med Sci Biol</i> . 1990 Oct;43(5):171-82.		
C45	KIMURA Y et al., Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. <i>J Biochem (Tokyo)</i> . 1994 Nov;116(5):991-4.		
C46	KLINMAN DM et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. <i>J Immunol</i> . 1997 Apr 15;158(8):3635-9.		
C47	KLINMAN DM et al., Immune recognition of foreign DNA: a cure for bioterrorism? <i>Immunity</i> . 1999 Aug;11(2):123-9.		
C48	KRIEG AM et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. <i>J Immunol</i> . 1989 Oct 15;143(8):2448-51.		
C49	KRIEG AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> . 1995 Apr 6;374(6522):546-9.		
C50	KRIEG AM et al., Leukocyte stimulation by oligodeoxynucleotides. In: <i>Applied Antisense Oligonucleotide Technology</i> , Stein CA and Krieg AM, eds., New York: Wiley-Liss, 1998; pp. 431-438.		

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C1039/7052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		FILING DATE: June 22, 2001	
		APPLICANT: Weiner et al.	
Sheet	5	of	EXAMINER: unknown

C51	KRIEG AM et al., Mechanism of action of CpG DNA. <i>Curr Top Microbiol Immunol.</i> 2000;247:1-21.		
C52	KRIEG AM et al., Mechanisms and therapeutic applications of immune stimulatory CpG DNA. <i>Pharmacol Ther.</i> 1999 Nov;84(2):113-20.		
C53	KRIEG AM et al., Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. <i>Proc Natl Acad Sci U S A.</i> 1993 Feb 1;90(3):1048-52.		
C54	KRIEG AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev.</i> 1996 Summer;6(2):133-9.		
C55	KRIEG AM et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? <i>Antisense Res Dev.</i> 1995 Winter;5(4):241.		
C56	KRIEG AM et al., The role of CpG dinucleotides in DNA vaccines. <i>Trends Microbiol.</i> 1998 Jan;6(1):23-7.		
C57	KRIEG AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. <i>Antisense Res Dev.</i> 1991 Summer;1(2):161-71.		
C58	KRIEG AM, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. <i>J Lab Clin Med.</i> 1996 Aug;128(2):128-33.		
C59	KRIEG AM, CpG DNA: a pathogenic factor in systemic lupus erythematosus? <i>J Clin Immunol.</i> 1995 Nov;15(6):284-92.		
C60	KRIEGER M et al., Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). <i>Annu Rev Biochem.</i> 1994;63:601-37.		
C61	KURAMOTO E et al., Oligonucleotide sequences required for natural killer cell activation. <i>Jpn J Cancer Res.</i> 1992 Nov;83(11):1128-31.		
C62	LAGNEAUX L et al., Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. <i>Blood.</i> 1998 Apr 1;91(7):2387-96.		
C63	LIPFORD GB et al., Bacterial DNA as immune cell activator. <i>Trends Microbiol.</i> 1998 Dec;6(12):496-500.		
C64	LIPFORD GB et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. <i>Eur J Immunol.</i> 1997 Sep;27(9):2340-4.		
C65	LIPFORD GB et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. <i>Eur J Immunol.</i> 1997 Dec;27(12):3420-6.		
C66	LYONS AB et al., Determination of lymphocyte division by flow cytometry. <i>J Immunol Methods.</i> 1994 May 2;171(1):131-7.		
C67	MACAYA RF et al., Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. <i>Proc Natl Acad Sci USA.</i> 1993 Apr 15;90(8):3745-9.		
C68	MACFARLANE DE et al., Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. <i>J Immunol.</i> 1998 Feb 1;160(3):1122-31.		
C69	MANZEL L et al., CpG-oligodeoxynucleotide-resistant variant of WEHI 231 cells. <i>J Leukoc Biol.</i> 1999 Nov;66(5):817-21.		
C70	MASTRANGELO MJ et al., Gene therapy for human cancer: an essay for clinicians. <i>Semin Oncol.</i> 1996 Feb;23(1):4-21.		
C71	MATSON S et al., Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. <i>Antisense Res Dev.</i> 1992 Winter;2(4):325-30.		
C72	McINTYRE KW et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. <i>Antisense Res Dev.</i> 1993 Winter;3(4):309-22.		
C73	MESSINA JP et al., Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. <i>J Immunol.</i> 1991 Sep 15;147(6):1759-64.		

12/27/02


FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C1039/7052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		FILING DATE: June 22, 2001	
		APPLICANT: Weiner et al.	
Sheet 6 of		GROUP ART UNIT: 1645	EXAMINER: unknown


	C74	MESSINA JP et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. <i>Cell Immunol.</i> 1993 Mar;147(1):148-57.		
	C75	MOJCIK CF et al., Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. <i>Clin Immunol Immunopathol.</i> 1993 May;67(2):130-6.		
	C76	MOLDOVEANU Z et al., CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. <i>Vaccine.</i> 1998 Jul;16(11-12):1216-24.		
	C77	MOTTRAM JC et al., A novel CDC2-related protein kinase from <i>Leishmania mexicana</i> , LmmCRK1, is post-translationally regulated during the life cycle. <i>J Biol Chem.</i> 1993 Oct 5;268(28):21044-52.		
	C78	NYCE JW et al., DNA antisense therapy for asthma in an animal model. <i>Nature.</i> 1997 Feb 20;385(6618):721-5.		
	C79	PACA-UCCARALERTKUN S et al., In vitro selection of DNA elements highly responsive to the human T-cell lymphotropic virus type I transcriptional activator, Tax. <i>Mol Cell Biol.</i> 1994 Jan;14(1):456-62.		
	C80	PISETSKY DS et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. <i>Mol Biol Rep.</i> 1993 Oct;18(3):217-21.		
	C81	PISETSKY DS et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. <i>Life Sci.</i> 1994;54(2):101-7.		
	C82	PISETSKY DS et al., The influence of base sequence on the immunological properties of defined oligonucleotides. <i>Immunopharmacology.</i> 1998 Nov;40(3):199-208.		
	C83	PISETSKY DS, Immunologic consequences of nucleic acid therapy. <i>Antisense Res Dev.</i> 1995 Fall;5(3):219-25.		
	C84	PISETSKY DS, The immunologic properties of DNA. <i>J Immunol.</i> 1996 Jan 15;156(2):421-3.		
	C85	RAZ E et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. <i>Proc Natl Acad Sci USA.</i> 1996 May 14;93(10):5141-5.		
	C86	ROMAN M et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. <i>Nat Med.</i> 1997 Aug;3(8):849-54.		
	C87	SATO Y et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. <i>Science.</i> 1996 Jul 19;273(5273):352-4.		
	C88	SCHNELL N et al., Identification and characterization of a <i>Saccharomyces cerevisiae</i> gene (PAR1) conferring resistance to iron chelators. <i>Eur J Biochem.</i> 1991 Sep 1;200(2):487-93.		
	C89	SHAN D et al., Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. <i>Blood.</i> 1998 Mar 1;91(5):1644-52.		
	C90	SHIRAKAWA T et al., The inverse association between tuberculin responses and atopic disorder. <i>Science.</i> 1997 Jan 3;275(5296):77-9.		
	C91	SPARWASSER T et al., Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. <i>Eur J Immunol.</i> 1998 Jun;28(6):2045-54.		
	C92	SPARWASSER T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol.</i> 1997 Jul;27(7):1671-9.		
	C93	STEC WJ et al., Diastereomers of nucleoside 3'-O-(2-thio-1,3,2-oxa(seleno)phospholanes): building blocks for stereocontrolled synthesis of oligo(nucleoside phosphorothioate)s. <i>J Am Chem Soc.</i> 1995 Dec 13;117(49):12019-29.		
	C94	STEIN CA et al., Oligodeoxynucleotides as inhibitors of gene expression: a review. <i>Cancer Res.</i> 1988 May 15;48(10):2659-68.		
	C95	STULL RA et al., Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. <i>Pharm Res.</i> 1995 Apr;12(4):465-83.		

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C1039/7052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 22, 2001	
		APPLICANT: Weiner et al.	
Sheet	7	of	GROUP ART UNIT: 1645
			EXAMINER: unknown

C96	SUBRAMANIAN PS et al., Theoretical considerations on the "spine of hydration" in the minor groove of d(CGCGAATTCGCG).d(GCGCTTAAGCGC): Monte Carlo computer simulation. <i>Proc Natl Acad Sci U S A</i> . 1988 Mar;85(6):1836-40.		
C97	SUN S et al., Mitogenicity of DNA from different organisms for murine B cells. <i>J Immunol</i> . 1997 Oct 1;159(7):3119-25.		
C98	TANAKA T et al., An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. <i>J Exp Med</i> . 1992 Feb 1;175(2):597-607.		
C99	THREADGILL DS et al., Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. <i>Vaccine</i> . 1998 Jan;16(1):76-82.		
C100	TSUKADA J et al., Transcription factors NF-IL6 and CREB recognize a common essential site in the human prointerleukin 1 beta gene. <i>Mol Cell Biol</i> . 1994 Nov;14(11):7285-97.		
C101	TUTT AL et al., Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. <i>J Immunol</i> . 1998 Sep 15;161(6):3176-85.		
C102	UHLMANN E et al., Antisense oligonucleotides: a new therapeutic principle. <i>Chem Rev</i> . 1990 Jun;90(4):543-84.		
C103	WAGNER RW, Gene inhibition using antisense oligodeoxynucleotides. <i>Nature</i> . 1994 Nov 24;372(6504):333-5.		
C104	WALLACE RB et al., Oligonucleotide probes for the screening of recombinant DNA libraries. <i>Methods Enzymol</i> . 1987;152:432-42.		
C105	WEINER GJ et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. <i>Proc Natl Acad Sci USA</i> . 1997 Sep 30;94(20):10833-7.		
C106	WOOLDRIDGE JE et al., Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. <i>Blood</i> . 1997 Apr 15;89(8):2994-8.		
C107	WU GY et al., Receptor-mediated gene delivery and expression in vivo. <i>J Biol Chem</i> . 1988 Oct 15;263(29):14621-4.		
C108	WU-PONG S, Oligonucleotides: opportunities for drug therapy and research. <i>Pharm Technol</i> . 1994 Oct;18:102-14.		
C109	WYATT JR et al., Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. <i>Proc Natl Acad Sci USA</i> . 1994 Feb 15;91(4):1356-60.		
C110	YAMAMOTO S et al., Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG. <i>Kekkaku</i> 1994;69(9):29-32.		
C111	YAMAMOTO T et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. <i>Microbiol Immunol</i> . 1994;38(10):831-6.		
C112	YAMAMOTO T et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. <i>Jpn J Cancer Res</i> . 1994 Aug;85(8):775-9.		
C113	YI AK et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. <i>J Immunol</i> . 1996 Jan 15;156(2):558-64.		
C114	ZHAO Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. <i>Antisense Res Dev</i> . 1993 Spring;3(1):53-66.		
C115	ZHAO Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. <i>Blood</i> . 1994 Dec 1;84(11):3660-6.		
C116	TOKUNAGA T et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. <i>Microbiol Immunol</i> . 1992;36(1):55-66.		

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C1039/7052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 22, 2001	
		APPLICANT: Weiner et al.	
Sheet 8 of		GROUP ART UNIT: 1645	EXAMINER: unknown

	C117	TOKUNAGA T et al., A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. <i>Jpn J Cancer Res.</i> 1988 Jun;79(6):682-6.		
	C118	YAMAMOTO T et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. <i>Antisense Res Dev.</i> 1994 Summer;4(2):119-22.		
	C119	YAMAMOTO S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. <i>Microbiol Immunol.</i> 1992;36(9):983-97.		
	C120	YAMAMOTO S et al., In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. <i>Jpn J Cancer Res.</i> 1988 Jul;79(7):866-73.		
	C121	YAMAMOTO S et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. <i>J Immunol.</i> 1992 Jun 15;148(12):4072-6.		

EXAMINER 	DATE CONSIDERED 12/27/02
--------------------------------------------------------------------------------------------	-----------------------------


#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

#13/I.D.S.

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C01039.70052.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 22,2001	
		APPLICANT: Weiner et al.	
		GROUP ART UNIT: 1635	EXAMINER: Angell
Sheet	1 of 1		



U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C157	JAHRSDORFER B et al., CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. <i>J Leukoc Biol.</i> 2001 Jan;69(1):81-8.		
	C158	KRIEG AM et al., Applications of immune stimulatory CpG DNA for antigen-specific immunotherapy. <i>Eur J Cancer</i> 1999;35 Supp 5:S10.		
	C159	WARREN TL et al., CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. <i>Clin Lymphoma.</i> 2000 Jun;1(1):57-61.		

RECEIVED

OCT 30 2002


TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED 12/24/02
----------	-----------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



#14/IDS

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C01039.70052.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 22, 2001	CONFIRMATION NO.: 7237
		APPLICANT: Weiner and Hartmann	
		GROUP ART UNIT: 1635	EXAMINER: Jon E. Angell
Sheet	1	of	1

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B32	WO	01/95935	A1	PCT	12-20-2001	
	B33	WO	01/22972	A2	PCT	04-05-2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)

EXAMINER	DATE CONSIDERED 12/24/02
----------	-----------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]